Since the milestone publication by Palmer et al. in 2006 [ 1 ], in which it was shown that mutations in the fi laggrin gene ( FLG ), which codes for fi laggrin "fi lament aggregating protein," signifi cantly increase the risk of atopic dermatitis (AD), fi laggrin and barrier dysfunction have been the epicenter of AD research and other skin diseases with decreased skin barrier function. Filaggrin is important for the aggregation of keratin fi laments forming the impenetrable keratin layer in the stratum corneum of the epidermis and also for the hydration of the skin through the "natural moisturizing factors" (NMFs) [ 2 ]. The decreased barrier function caused by the lack of fi laggrin expression may increase the risk of allergic sensitization and thus offer a molecular background for the so-called atopic march, in which patients suffering from early childhood AD have a higher risk of developing asthma, rhinitis, and food allergies [ 3 ]. An interesting fact is that 44-85.8 % of AD patients do not carry an FLG mutation, but still all patients have a decreased skin barrier function [ 4 ], and that among patients carrying an FLG mutation, 40 % never show any signs of decreased skin barrier function [ 5 ].These results indicate that regulatory mechanisms other than null mutations in the FLG are responsible for the decreased skin barrier function in AD patients. Mutations in other genes involved in the skin barrier function have been linked to the development of AD such as SPINK5 (LEKTI), a serine protease inhibitor, which inhibits the